Ra Pharmaceuticals, Inc. Balance Sheet

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016
Assets
Current assets:
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Goodwill
Intangible assets, net
Operating lease right-of-use assets, net
Restricted cash
Other assets
Total assets
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses
Operating lease liabilities
Deferred rent
Total current liabilities
Operating lease liabilities, net of current portion
Deferred rent, net of current portion
Deferred tax liabilities
Total liabilities
Redeemable convertible preferred stock
Series A redeemable convertible preferred stock
Series B-1 redeemable convertible preferred stock
Series B-2 redeemable convertible preferred stock
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 150,000 shares authorized; 47,222 and 42,072 shares issued and outstanding as of December 31, 2019 and 2018, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments